Optima projects robust growth for Greece's Helleniq Energy and Lavipharm

Optima forecasts a strong quarter for Helleniq Energy, projecting adjusted EBITDA of €382 million—a 73% year‑on‑year rise—driven by a favorable refining environment despite maintenance at the Aspropyrgos plant. The analyst also expects adjusted net profit of €205 million, up from €72 million in 2Q25, bolstered by inventory gains of €200 million linked to higher oil prices. Currency movements slightly moderated margins, but the overall outlook remains upbeat.

For Lavipharm, Optima projects average annual sales growth of 25.9% from 2025‑2030, with EBITDA increasing 34.5% yearly. The firm assigns a target share price of €2.08 and highlights growth drivers such as the launch of a medical‑cannabis product, a new OTC antiseptic partnership with iNova, and the acquisition of Durogesic rights in 24 countries, expected to lift profitability when production shifts to Lavipharm facilities after 2027.